I think it will sink to around $4. There is a lot of tough competition for this drug, and even if it is approved, I think the sales will be poor. The side-effects put it at a marked disadvantage to new-generation RNAI therapeutics.
share price, page-4
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
